KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Liabilities (2016 - 2025)

Historic Total Liabilities for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $11.2 million.

  • TherapeuticsMD's Total Liabilities fell 988.12% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 988.12%. This contributed to the annual value of $11.5 million for FY2024, which is 1832.83% down from last year.
  • As of Q3 2025, TherapeuticsMD's Total Liabilities stood at $11.2 million, which was down 988.12% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Total Liabilities registered a high of $274.0 million during Q1 2022, and its lowest value of $11.2 million during Q2 2025.
  • In the last 5 years, TherapeuticsMD's Total Liabilities had a median value of $22.5 million in 2023 and averaged $99.6 million.
  • Per our database at Business Quant, TherapeuticsMD's Total Liabilities soared by 17599.16% in 2021 and then tumbled by 8993.4% in 2023.
  • Over the past 5 years, TherapeuticsMD's Total Liabilities (Quarter) stood at $263.1 million in 2021, then crashed by 78.98% to $55.3 million in 2022, then tumbled by 74.65% to $14.0 million in 2023, then dropped by 18.33% to $11.5 million in 2024, then decreased by 1.96% to $11.2 million in 2025.
  • Its Total Liabilities was $11.2 million in Q3 2025, compared to $11.2 million in Q2 2025 and $11.5 million in Q1 2025.